Barbados
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 1.03 (0.08 - 12.06) | 2015 | Modelled | WHO |
| 1.4 (0.67 - 2.91) | 2013 | Modelled | Schweitzer et al, 2015 |
| 0.43 (0.35 - 0.50) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 0.46 (0.38 - 0.53) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.46 (0.38 - 0.54) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.47 (0.39 - 0.53) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.47 (0.39 - 0.54) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.47 (0.40 - 0.54) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.48 (0.40 - 0.55) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.49 (0.41 - 0.56) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.51 (0.42 - 0.58) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.51 (0.42 - 0.59) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.52 (0.43 - 0.59) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.53 (0.44 - 0.60) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.54 (0.45 - 0.61) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.54 (0.45 - 0.63) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.55 (0.46 - 0.63) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.55 (0.46 - 0.63) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.55 (0.46 - 0.64) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.55 (0.46 - 0.64) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.55 (0.46 - 0.64) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.56 (0.46 - 0.65) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.56 (0.47 - 0.65) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.57 (0.47 - 0.65) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.58 (0.48 - 0.66) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.59 (0.49 - 0.67) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.59 (0.49 - 0.68) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.59 (0.49 - 0.68) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.59 (0.49 - 0.68) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.59 (0.49 - 0.68) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.58 (0.48 - 0.69) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.58 (0.48 - 0.69) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.46 (0.38 - 0.53) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.34 (0.02 - 4.81) | 2015 | Modelled | WHO |
| 0.03 (0.02 - 0.05) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 0.04 (0.03 - 0.06) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.04 (0.03 - 0.06) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.04 (0.03 - 0.06) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.04 (0.03 - 0.06) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.04 (0.03 - 0.06) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.05 (0.03 - 0.06) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.06 (0.04 - 0.07) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.06 (0.04 - 0.08) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.07 (0.05 - 0.09) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.07 (0.05 - 0.10) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.07 (0.05 - 0.10) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.07 (0.05 - 0.10) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.07 (0.05 - 0.10) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.07 (0.05 - 0.10) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.07 (0.05 - 0.10) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.08 (0.06 - 0.11) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.1 (0.07 - 0.13) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.12 (0.09 - 0.17) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.15 (0.11 - 0.21) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.18 (0.13 - 0.25) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.22 (0.15 - 0.29) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.27 (0.19 - 0.36) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.33 (0.23 - 0.42) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.37 (0.25 - 0.48) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.38 (0.26 - 0.50) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.38 (0.26 - 0.50) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.38 (0.27 - 0.50) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.38 (0.26 - 0.50) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.38 (0.26 - 0.50) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.37 (0.26 - 0.50) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.18 (0.05 - 0.55) | 2020 | Modelled | WHO |
Showing out of
Show more
Number of people living with chronic HBV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 1,279 (1,053 - 1,491) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 1,321 (1,092 - 1,536) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,323 (1,089 - 1,535) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,324 (1,089 - 1,537) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,322 (1,106 - 1,517) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,321 (1,113 - 1,514) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,328 (1,121 - 1,516) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,346 (1,126 - 1,534) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,366 (1,136 - 1,558) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,384 (1,144 - 1,575) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,391 (1,149 - 1,596) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,394 (1,156 - 1,592) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,402 (1,166 - 1,606) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,410 (1,173 - 1,618) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,415 (1,184 - 1,630) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,411 (1,177 - 1,637) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,402 (1,169 - 1,623) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,393 (1,157 - 1,613) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,386 (1,144 - 1,610) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,380 (1,142 - 1,600) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,377 (1,133 - 1,602) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,382 (1,144 - 1,593) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,397 (1,160 - 1,601) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,416 (1,177 - 1,617) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,432 (1,194 - 1,639) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,438 (1,199 - 1,663) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,438 (1,194 - 1,660) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,436 (1,186 - 1,664) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,433 (1,182 - 1,671) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,428 (1,177 - 1,676) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,419 (1,164 - 1,685) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 2.04 (1.50 - 2.67) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 2.61 (2.01 - 3.30) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.6 (2.01 - 3.28) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.72 (2.13 - 3.45) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.77 (2.16 - 3.54) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.67 (2.07 - 3.40) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.78 (2.18 - 3.56) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.75 (2.14 - 3.50) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.71 (2.12 - 3.44) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.37 (1.87 - 2.99) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.6 (2.03 - 3.33) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.44 (1.92 - 3.11) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.33 (1.84 - 2.94) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.27 (1.79 - 2.85) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.38 (1.88 - 3.01) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.39 (1.88 - 3.02) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.39 (1.88 - 3.03) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.38 (1.86 - 3.02) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.28 (1.77 - 2.89) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.15 (1.69 - 2.73) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.99 (1.56 - 2.53) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.91 (1.51 - 2.41) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.86 (1.47 - 2.36) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.81 (1.43 - 2.31) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.79 (1.39 - 2.29) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.79 (1.38 - 2.30) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.8 (1.38 - 2.34) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.84 (1.39 - 2.40) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.89 (1.41 - 2.48) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.95 (1.46 - 2.53) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.04 (1.50 - 2.67) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related deaths
National
Download
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 90 | 2019 | Survey/reported | WHO/UNICEF |
| 85 | 2020 | Survey/reported | WHO/UNICEF |
| 82 | 2021 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
HBV National Action Plan
HBV elimination goal
Eligible for HBV generic medicines
HepB birth dose policy
No
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 1.85 (1.50 - 2.27) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.84 (1.51 - 2.26) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.83 (1.50 - 2.25) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.81 (1.48 - 2.20) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.78 (1.45 - 2.20) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.78 (1.45 - 2.19) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.77 (1.45 - 2.18) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.77 (1.44 - 2.18) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.77 (1.44 - 2.18) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.76 (1.43 - 2.19) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.77 (1.44 - 2.19) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.77 (1.44 - 2.20) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.78 (1.45 - 2.21) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.78 (1.46 - 2.21) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.79 (1.47 - 2.22) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.8 (1.47 - 2.24) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.81 (1.48 - 2.24) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.82 (1.48 - 2.24) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.82 (1.49 - 2.24) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.83 (1.49 - 2.26) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.83 (1.49 - 2.26) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.83 (1.49 - 2.25) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.83 (1.49 - 2.25) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.83 (1.48 - 2.25) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.82 (1.48 - 2.26) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.82 (1.48 - 2.25) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.82 (1.48 - 2.26) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.83 (1.48 - 2.26) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.83 (1.48 - 2.26) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.83 (1.48 - 2.28) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.78 (1.45 - 2.19) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Number of people living with chronic HCV (RNA+/cAg)
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 4,468 (3,615 - 5,551) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,460 (3,620 - 5,521) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,453 (3,622 - 5,523) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,447 (3,608 - 5,511) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,443 (3,597 - 5,469) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,444 (3,599 - 5,487) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,451 (3,612 - 5,473) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,462 (3,637 - 5,512) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,478 (3,654 - 5,507) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,498 (3,663 - 5,563) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,520 (3,689 - 5,604) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,542 (3,709 - 5,595) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,560 (3,719 - 5,633) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,577 (3,741 - 5,678) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,595 (3,770 - 5,701) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,622 (3,792 - 5,737) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,652 (3,812 - 5,754) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,680 (3,826 - 5,792) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,710 (3,847 - 5,844) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,745 (3,862 - 5,904) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,790 (3,886 - 5,949) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,838 (3,937 - 5,995) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,884 (3,990 - 6,039) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,930 (4,026 - 6,067) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,980 (4,061 - 6,148) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5,036 (4,096 - 6,220) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5,129 (4,204 - 6,264) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5,223 (4,284 - 6,430) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5,281 (4,349 - 6,465) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5,299 (4,318 - 6,518) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 5,324 (4,340 - 6,544) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HCV-related death rate
National
Download| Value (Deaths per 100,000) | Year | Type | Source |
|---|---|---|---|
| 3.82 (2.74 - 5.18) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 3.37 (2.59 - 4.32) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.31 (2.54 - 4.22) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.46 (2.68 - 4.40) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.4 (2.62 - 4.34) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.51 (2.72 - 4.46) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.54 (2.74 - 4.51) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.51 (2.74 - 4.46) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.49 (2.72 - 4.41) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.39 (2.62 - 4.29) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.16 (2.47 - 4) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.22 (2.50 - 4.07) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.03 (2.38 - 3.83) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.11 (2.45 - 3.92) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.16 (2.50 - 4.01) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.17 (2.50 - 3.98) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.18 (2.47 - 4.02) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.15 (2.47 - 3.99) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.18 (2.47 - 4.02) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.19 (2.46 - 4.03) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.17 (2.48 - 4.04) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.15 (2.45 - 4.01) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.26 (2.52 - 4.20) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.21 (2.50 - 4.12) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.19 (2.49 - 4.06) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.35 (2.56 - 4.37) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.4 (2.55 - 4.52) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.46 (2.58 - 4.57) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.54 (2.64 - 4.70) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.65 (2.66 - 4.86) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.82 (2.74 - 5.18) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HCV-related deaths
National
Download
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download
Showing out of
Show more
HBV National Action Plan
HBV elimination goal
Eligible for HBV generic medicines
HepB birth dose policy
No
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
Survey/surveillance
No data available
No data available
Hepatitis related deaths (national)
Modelled
HBV
6
2019
(4 - 8)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HBV chart
Modelled
HCV
11
2019
(8 - 15)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HCV chart
Prevalence < 5
HBV
0.18
(%)
2020, latest modelled
(0.05 - 0.55(%))
WHO
Prevalence PWID
No data available
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
No. of syringes/PWID/year
Survey/surveillance
No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines